Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + R-GemOx in relapsed or refractory diffuse large B-cell lymphoma
2016-002654-21Phase 2Unknown
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival rate at 1 year. Status: unknown.
02
Drugs
atezolizumabrituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-002654-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002654-21.